The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
Why Do Board Directors And CEOs Need To Value UN Sustainability Goal 8? - Sustainable Economic Growth, And Productive Employment For All forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Covid vaccine: Oxford to deliberately reinfect recovered patients
Top Searches
Covid vaccine: Oxford to deliberately reinfect recovered patients
Bloomberg / Apr 19, 2021, 09:07 IST
FacebookTwitterLinkedinEMail
One of the goals of the Oxford study is to determine how much time it takes to infect someone who’s had the virus earlier.
LONDON: People who have fought off the Covid-19 virus will be deliberately reinfected in a first-of-its-kind trial at the University of Oxford that may shed light on how to develop more effective vaccines against the pathogen.
Researchers are looking for 64 healthy, previously Covid-infected volunteers from 18 to 30 years old to be studied under controlled, quarantined conditions for at least 17 days, the UK university said Monday. Participants will be infected with the original strain from Wuhan, China and followed for a year.
Oxford study indicates AstraZeneca effective against Brazil variant, source says
SECTIONS
Last Updated: Mar 05, 2021, 08:29 PM IST
Share
Synopsis
The data indicates that the vaccine will not need to be modified in order to protect against the variant, which is believed to have originated in the Amazonian city of Manaus, said the source, who requested anonymity as the results have not yet been made public.
Agencies
The source did not provide the exact efficacy of the vaccine against the variant. They said the full results of the study should be released soon, possibly in March.
Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.